Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P395 Management of pouch vaginal fistulae in ulcerative colitis: A 35-year experience

ECCO'20 Vienna

Year: 2020
Authors:

L. REZA1, E. Van Praag2, N. Iqbal1, C. Twum-Barima1, A. Hart3,4, S. Clark5,6, P. Tozer1,6

1St Mark’s Academic Institute, Fistula research Unit, London, UK, 2Academic Medical Centre, Colorectal surgery, Amsterdam, The Netherlands, 3St Mark’s Academic Institute, Inflammatory Bowel Disease Research Unit, London, UK, 4Imperial College, Faculty of Medicine, London, UK, 5St Mark’s Academic Institute, Colorectal Surgery, London, UK, 6Imperial College, Department of Surgery and Cancer, London, UK

P396 Pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects

ECCO'20 Vienna

Year: 2020
Authors:

C.A. Lee1, L. Acevedo1, D.A. Oh1, P. Baweja1, K. Gilder1, D. Han2, S. Jhee2, K. Komori1, S. Mullin1, T. Nguyen-Cleary1, K. Schmelzer2, Y. Tang1, J. Zhang1, J. Grundy1

1Arena Pharmaceuticals Inc., n/a, San Diego, USA, 2PAREXEL International, n/a, Waltham, USA

P397 Surveillance in ulcerative colitis: Can we predict the risk for intraepithelial neoplasia?

ECCO'20 Vienna

Year: 2020
Authors:

J. Estorninho1, P. Freire2, S. Lopes1, M. Ferreira1, M. Ferreira1, F. Portela1, P. Figueiredo1

1Centro Hospitalar e Universitário de Coimbra, Serviço de Gastrenterologia, Coimbra, Portugal, 2Faculdade de Medicina da Universidade de Coimbra, Gastrenterologia, Coimbra, Portugal

P398 The early appearance of anti-drug antibodies during the induction phase predicts the clinical response of adalimumab and infliximab in IBD

ECCO'20 Vienna

Year: 2020
Authors:

X. Roblin1, N. williet1, P. veyrard1, G. boschetti2, A.E. berger3, S. nancey2, B. flourie2, S. paul3

1Department of Gastroenterology and Hepatology- Inserm- CIC1408, CHU Saint Etienne - Hospital Nord, Saint-Priest en Jarez, France, 2Department of Gastroenterology and Hepatology, CHU Lyon sud, Lyon, France, 3CHU Saint Etienne - Hospital Nord, Immunology, Saint-Priest en Jarez, France

P399 Endoscopic and histologic outcome in tofacitinib treated refractory moderate-to-severe ulcerative colitis: A prospective real-life cohort

ECCO'20 Vienna

Year: 2020
Authors:

B. Verstockt1, A. Outtier1, J. Lefrère1, J. Sabino1, S. Vermeire1, G. De Hertogh2, M. Ferrante2

1IBD Leuven, 1Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 2Laboratory of Morphology and Molecular Pathology, University Hospitals Leuven, Leuven, Belgium

P400 Understanding the impact of TNF-α antagonists on the severity of non-melanoma skin cancer in inflammatory bowel disease and the consequences for therapy

ECCO'20 Vienna

Year: 2020
Authors:

C. Townsend, R. Khanna, A.S. Wilson

Gastroenterology, Western University, London, Canada

P401 Sarcopenia in children and young adults with primary sclerosing cholangitis and IBD

ECCO'20 Vienna

Year: 2020
Authors:

E. Shteyer1, R. Cytter-Kuint2, L. Winberg2

1Department of Pediatric Gastroenterology, Shaare Zedek Medical Center, Jerusalem, Israel, 2Departement of Radiology, Shaare Zedek Medical Center, Jerusalem, Israel

P402 Prediction of emergency department re-visit among Crohn’s disease patients: a retrospective study

ECCO'20 Vienna

Year: 2020
Authors:

H. Mahajna1, Y. Barash2, B. Ungar1, S. Soffer2, S. Ben-Horin1, E. Klang2, U. Kopylov1

1Department of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel, 2Department of Diagnostic Imaging, Sheba Medical Center, Ramat Gan, Israel

P403 Post hoc examination of VISIBLE 1 data for baseline predictors of response to 2 or 3 IV doses of vedolizumab for adults with moderate-to-severe ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

W. Sandborn1, E.V. Loftus Jr2, F. Baert3, J. Jansson4, J. Chen4, N. Candela5, K. Lasch5, K. Kisfalvi4

1Division of Gastroenterology, University of California San Diego, La Jolla, USA, 2Gastroenterology, Mayo Clinic, Rochester, USA, 3Department of Gastroenterology and Hepatology, AZ Delta, Roeselare, Belgium, 4Gastroenterology, Takeda Development Center Americas Inc., Cambridge, USA, 5Gastroenterology, US Medical Office- Takeda Pharmaceuticals U.S.A.- Inc., Deerfield, USA

P404 Prolonged steroid exposure prior to admission is associated with increased likelihood of rescue therapy and colectomy in acute severe ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

A. Barnes1,2, P. Spizzo1

1Gastroenterology, Flinders Medical Centre, Adelaide, Australia, 2College of Medicine and Public Health, Flinders University, Adelaide, Australia

P405 Comparison of long-term outcomes of infliximab vs. adalimumab in 1488 biologic-naive Korean patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

Y.S. Jung Prof. Dr.1, M. Han2, S. Park3, J.H. Cheon4

1Internal Medicine, Kangbuk Samsung Hospital, Seoul, Republic of Korea, 2Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea, 3Biostatistics, Yonsei University, Seoul, Republic of Korea, 4Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

P406 Adherence, acceptability and serum trough concentration of adalimumab autoinjector in quiescent patients with inflammatory bowel diseases

ECCO'20 Vienna

Year: 2020
Authors:

S. Kato, N. Yamaga, A. Ishibashi, K. Kani, S. Nagoshi

Department of Gastroenterology and Hepatology, Saitama Medical Centre- Saitama Medical University, Kawagoe City, Saitama, Japan

P407 Is the rapid infliximab infusion a safe and cost-saving strategy in paediatric inflammatory bowel disease?

ECCO'20 Vienna

Year: 2020
Authors:

G. Pujol Muncunill1, J. Martínez-Osorio1, F. Bossacoma-Busquets2, L. Álvarez-Carnero1, J. Arrojo-Juárez2, V. Vila-Miravet1, F.J. Martin De Carpi1

1Department of Pediatric Gastroenterology- Hepatology and Nutrition, Hospital Sant Joan de Déu, Unit for the Comprehensive Care of Pediatric Inflammatory Bowel Disease, Esplugues del Llobregat, Spain, 2Pharmacy Department, Hospital Sant Joan de Déu, Esplugues del Llobregat, Spain

P408 Long-term impact of the decrease of infliximab trough levels on the disease course in Inflammatory Bowel Disease patients under maintenance treatment with infliximab

ECCO'20 Vienna

Year: 2020
Authors:

E. Orfanoudaki1, M. Gazouli2, K. Foteinogiannopoulou1, E. Theodoraki1, E. Legaki2, I. Koutroubakis1

1Gastroenterology, University Hospital of Heraklion, Heraklion Crete, Greece, 2Laboratory of Biology- Department of Basic Medical Science, National and Kapodistrian University of Athens, Athens, Greece

P409 Endoscopic and histological activity is associated with non-response to biologic therapy in ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

S. WANN1, R. Norris1, R. Williams2, C. Basnayake1, M. Lust1, E. Wright1, M. Kamm1, W. Connell1, A. Thompson1, N. Ding1

1Gastroenterology, St Vincent’s Hospital Melbourne, Melbourne, Australia, 2Anatomical Pathology, St Vincent’s Hospital Melbourne, Melbourne, Australia

P410 Could the disease become ‘a friend’? The mediating role of illness acceptance on self-efficacy and quality of life of gastroenterological patients

ECCO'20 Vienna

Year: 2020
Authors:

A. Rudnik1,2, G. Piotrowicz2, G. Rydzewska3,4, M. Bidzan1, E. Ozgo5

1Institute of Psychology, University of Gdansk, Gdańsk, Poland, 2Department of Gastroenterology, Clinical Hospital of the Ministry of the Interior and Administration in Gdansk, Gdansk, Poland, 3Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Subdivision, Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Warsaw, Poland, 4Department of the Prevention of Alimentary Tract Diseases- Faculty of Medicine and Health Science, Jan Kochanowski University, Kielce, Poland, 5Division of Psychiatry, University College London, London, UK

P411 Faecal calprotectin is more tightly associated with endoscopic disease activity compared with other biomarkers in patients with inflammatory bowel disease under maintenance treatment with adalimumab

ECCO'20 Vienna

Year: 2020
Authors:

E. Orfanoudaki, E. Theodoraki, K. Foteinogianopoulou, A. Mantaka, I. Koutroubakis

Gastroenterology, University Hospital of Heraklion, Heraklion Crete, Greece

P412 Maintenance therapy of vedolizumab (VDZ) after induction of remission by tacrolimus (TAC) in patients with refractory ulcerative colitis (UC)

ECCO'20 Vienna

Year: 2020
Authors:

A. Ito, M. Shun, O. Teppei, T. Katsutoshi

Department of Gastroenterology- Department of Medicine, Tokyo Women’s Medical University Hospital, Tokyo, Japan

P413 General impressions about nutrition in patients with inflammatory bowel disease using a nutritional survey

ECCO'20 Vienna

Year: 2020
Authors:

M.A. Ruiz-Ramirez1, C. Suarez1, J. Poza1, E. Martin-Arranz1, J.L. Rueda-Garcia1, M. Sanchez-Azofra1, M. Cuadros1, P. Mayor1, L. Garcia-Ramirez2, M.D. Martin-Arranz1

1Gastroenterology, Hospital Universitario La Paz, Madrid, Spain, 2Clinical Trials, Hospital Universitario La Paz, Madrid, Spain

P414 Risk factors for the development of anti-drug antibodies to infliximab and adalimumab in Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

E. Khoo1, A. Lord2, K. Hanigan1, A. Croft1, G. Radford-Smith1,2

1Royal Gastroenterology Department, Brisbane and Women’s Hospital, Herston, Australia, 2QIMR Berghofer Medical Research Institute, Gut Health Laboratory, Herston, Australia